Background: The efficacy and tolerability of the regimen containing paclitaxel and cisplatin (TP) in the neo-adjuvant treatment of locally advanced squamous cell cervical cancer are unknown. The TIP regimen (TP plus ifosfamide) showed high efficacy but high toxicity and it is used as an internal control.
Patients And Methods: In all, 154 patients were randomized to TP (paclitaxel 175 mg/m(2) + cisplatin 75 mg/m(2); n = 80) or TIP (TP + ifosfamide 5 g/m(2); n = 74), three cycles, followed by radical surgery. Pathological response to chemotherapy was classified as optimal [no residual tumor (complete response) or residual disease with < or = 3 mm stromal invasion (PR1)] or suboptimal response.
Results: Patient characteristics (TP/TIP): stage IB2 (56%/64%), IIA (18%/14%), IIB (20%/19%), III-IVA (5%/4%) and median age (42 years/45 years). The optimal response rate in the TP group was 25%, 95% confidence interval (CI) = 16% to 37% and 43%, 95% CI = 31% to 55% in the TIP group. Grades 3-4 leukopenia (6%/53%) and neutropenia (26%/76%) were significantly more frequent on TIP.
Conclusion: TP performance was below expectation since the lower 95% confidence limit of the optimal response rate failed to reach the prespecified minimum requirement of efficacy, i.e. 22%. The TIP regimen confirmed its activity but was associated with higher haematological toxicity than TP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/annonc/mdn690 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer.
Taiwan J Obstet Gynecol
January 2025
Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. Electronic address:
Objective: To investigate the real-world efficacy and toxicity of paclitaxel-cisplatin-bevacizumab and identify prognostic factors for paclitaxel-cisplatin-bevacizumab in platinum-naïve primary stage IVB cervical cancer.
Materials And Methods: We retrospectively reviewed patients with stage IVB cervical cancer who received paclitaxel-cisplatin-bevacizumab as first-line treatment between July 2015 and December 2021 at Asan Medical Center, Korea. Patient data including clinicopathologic characteristics, imaging, paclitaxel-cisplatin-bevacizumab administration, recurrence, and survival were collected.
The surgical safety margin after neoadjuvant chemotherapy combined with nimotuzumab leading to tumor regression.
J Chin Med Assoc
December 2024
Department of Stomatology, The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital, Hebei, China.
Background: To investigate the effect of nimotuzumab (N) combined with nab-paclitaxel, cisplatin, and fluorouracil (APF) neoadjuvant chemotherapy on the surgical margin.
Methods: 55 patients were divided into three groups: neoadjuvant chemotherapy and surgery group (G1, 15 cases), chemotherapy and surgery group (G2 group, 20 cases), and surgery group (G3 group, 20 cases). Tissue samples of the tumor core zone (P0), adjacent (P1, 3-5mm from tumor), distal adjacent (P2, 7-10mm from tumor), and surgical margin (P3, 15mm from tumor) were collected.
CD8 + T-Cell-Related Genes: Deciphering Their Role in the Pancreatic Adenocarcinoma TME and Their Effect on Prognosis.
Dig Dis Sci
January 2025
Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, No. 59 Haier Road, Qingdao, 266000, Shandong, China.
Article Synopsis
- Immunotherapy and targeted therapies struggle to effectively treat pancreatic adenocarcinoma (PAAD) due to its unique tumor microenvironment (TME), highlighting the importance of CD8+ T cells in this context.
- * Researchers utilized gene coexpression network analysis and algorithms to assess PAAD data from The Cancer Genome Atlas, aiming to understand CD8+ T-cell infiltration and develop a risk score model for patient prognosis.
- * A validated risk model, based on five CD8-related genes, indicated that patients in a low-risk group had better survival outcomes, while also finding correlations between tumor mutation burden and immune function associated with the risk score.
Diaphragm epithelioid hemangioendothelioma: a rare case report.
BMC Geriatr
November 2024
Cancer Prevention and Treatment Institute of Chengdu, Department of Oncology, The Second Clinical Medical College, Chengdu Fifth People's Hospital, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Article Synopsis
- * A case study details a 75-year-old male with symptoms like cough and chest tightness who was diagnosed with Diaphragm EHE after a biopsy, and despite receiving chemotherapy and targeted therapy treatment, he experienced disease progression.
- * The study concludes that EHE associated with pleural effusion tends to progress rapidly, indicating challenges in managing such cases.
Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series.
J Dermatol
January 2025
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Article Synopsis
- Immune checkpoint inhibitors (ICIs), like pembrolizumab (PEM), are effective against tumors but can cause serious skin side effects (cutaneously adverse events or CAEs), especially when used in combination therapies.
- Severe CAEs may require stopping the immunotherapy, and the risk is higher when ICIs are used with other treatments compared to when they are used alone.
- A case study of 19 women with advanced cervical cancer highlighted the occurrence of severe CAEs, including erythema multiforme and anaphylaxis, stressing the need for tight monitoring of skin reactions during PEM combination therapy to ensure patient safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!